Ewing Sarcoma Clinical Trials
Ewing Sarcoma studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect ewing sarcoma clinical trial.
Condition
Ewing Sarcoma
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Ewing Sarcoma Clinical Trials
Phase-Based Estimates
1
Effectiveness
2
Safety
Cryoablation Therapy
for Cancer
Washington, United States
< 65
All Sexes
Phase 2
Recruiting
Metastatic
Washington, United States
< 65
All Sexes
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.
Phase-Based Estimates
1
Effectiveness
2
Safety
LY2880070
for Ewing Sarcoma
New York, NY
Any Age
All Sexes
Phase 2
Recruiting
Locally Advanced
New York, NY
Any Age
All Sexes
The purpose of this study is to find out whether LY2880070 combined with the chemotherapy drug gemcitabine is an effective treatment for Ewing sarcoma or Ewing-like sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Surufatinib In Combination With Gemcitabine
for Sarcoma
Orange, CA
< 65
All Sexes
Phase 1 & 2
Recruiting
Grade I
Orange, CA
< 65
All Sexes
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.
Phase-Based Estimates
1
Effectiveness
1
Safety
PEN-866
for Neuroectodermal Tumors, Primitive, Peripheral
Bethesda, MD
< 65
All Sexes
Phase 1 & 2
Waitlist Available
Grade I
Bethesda, MD
< 65
All Sexes
Background: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma. Researchers want to learn if combining PEN-866 with other drugs can treat certain cancers in adolescents and young adults. Objective: To learn if the combination of PEN-866 with vincristine and temozolomide can be used to treat adolescents and young adults with solid tumors that have returned after or did not respond to standard treatments, or for which there are no standard treatments. Eligibility: People ages 12-39 years who have solid tumors, Ewing sarcoma, or rhabdomyosarcoma that returned after or did not respond to standard treatments. Design: Participants will be screened with a medical history, physical exam, and eye exam. They will have heart function tests. They may have imaging scans of the chest, abdomen, and pelvis. They will give blood and urine samples. They may have a tumor biopsy. Some samples will be used for genetic testing. Some screening tests will be repeated during the study. Participants will get 3 drugs for up to 18 cycles. Each cycle lasts 21 days. They will get PEN-866 and vincristine by IV infusion (a tube in their vein) on Days 1 and 8 of each cycle. They will take temozolomide by mouth on Days 1-5 of each cycle. Participants will complete questionnaires about their physical, mental, and social health. Participants will have a follow-up visit 30 days after treatment ends. They may be contacted by phone or email for the rest of their life.
Phase-Based Estimates
1
Effectiveness
1
Safety
Second Generation 4-1BBζ B7H3-EGFRt-DHFR(selected) And A Second Generation 4-1BBζ CD19-Her2tG
for Cancer
Seattle, WA
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Seattle, WA
< 65
All Sexes
This study is evaluating whether genetically modified T cells may be able to
Phase-Based Estimates
1
Effectiveness
1
Safety
Vorinostat
for Sarcoma, Ewing
Valhalla, NY
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Valhalla, NY
< 65
All Sexes
Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of vorinostat that can be given together with vincristine, irinotecan, and temozolomide without causing severe side effects; To learn what kind of side effects this four drug combination can cause; To learn about the effects of vorinostat and the combination of vorinostat, vincristine, irinotecan, and temozolomide on specific molecules in tumor cells; To determine whether the combination of vorinosat, vincristine, irinotecan, and temozolomide is a beneficial treatment.
Phase-Based Estimates
1
Effectiveness
2
Safety
Palbociclib
for Sarcoma
Boston, MA
< 65
All Sexes
Phase 2
Waitlist Available
Grade II
Boston, MA
< 65
All Sexes
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: Palbociclib Ganitumab
Phase-Based Estimates
1
Effectiveness
1
Safety
Irinotecan
for Sarcoma, Ewing
Bethesda, MD
Any Age
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Bethesda, MD
Any Age
All Sexes
This study is evaluating whether a combination of two drugs may help treat a type of bone cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Combination Metyrosine-derivative, Low-dose Methoxsalen, Phenytoin And Sirolimus (MPS)
for Sarcoma, Ewing
Santa Monica, CA
Any Age
All Sexes
Phase 2
Recruiting
Grade II
Santa Monica, CA
Any Age
All Sexes
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment Clinically advanced sarcoma patients in the salvage treatment setting Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.
Phase-Based Estimates
1
Effectiveness
1
Safety
INBRX-109
for Adenocarcinoma
Grand Rapids, MI
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Grand Rapids, MI
18+
All Sexes
This study is evaluating whether a new drug may help treat cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Palbociclib
for Cancer
Montreal, Canada
< 65
All Sexes
Phase 2
Recruiting
Grade I
Montreal, Canada
< 65
All Sexes
This study is evaluating whether a drug may help children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Second Generation 4-1BBζ EGFR806-EGFRt And A Second Generation 4 1BBζ CD19-Her2tG
for Cancer
Seattle, WA
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Seattle, WA
< 65
All Sexes
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a EGFR-specific receptor (chimeric antigen receptor, or CAR) that will target and kill solid tumors that express EGFR and the selection-suicide marker EGFRt. EGFRt is a protein incorporated into the cell with our EGFR receptor which is used to identify the modified T cells and can be used as a tag that allows for elimination of the modified T cells if needed. On Arm A of the study, research participants will receive EGFR-specific CAR T cells only. On Arm B of the study, research participants will receive CAR T cells directed at EGFR and CD19, a marker on the surface of B lymphocytes, following the hypothesis that CD19+ B cells serving in their normal role as antigen presenting cells to T cells will promote the expansion and persistence of the CAR T cells. The CD19 receptor harbors a different selection-suicide marker, HERtG. The primary objectives of the study will be to determine the feasibility of manufacturing the cell products, the safety of the T cell product infusion, to determine the maximum tolerated dose of the CAR T cells products, to describe the full toxicity profile of each product, and determine the persistence of the modified cell in the subject's body on each arm. Subjects will receive a single dose of T cells comprised of two different subtypes of T cells (CD4 and CD8 T cells) felt to benefit one another once administered to the research participants for improved potential therapeutic effect. The secondary objectives of this protocol are to study the number of modified cells in the patients and the duration they continue to be at detectable levels. The investigators will also quantitate anti-tumor efficacy on each arm. Subjects who experience significant and potentially life-threatening toxicities (other than clinically manageable toxicities related to T cells working, called cytokine release syndrome) will receive infusions of cetuximab (an antibody commercially available that targets EGFRt) or trastuzumab (an antibody commercially available that targets HER2tG) to assess the ability of the EGFRt on the T cells to be an effective suicide mechanism for the elimination of the transferred T cell products.
Phase-Based Estimates
1
Effectiveness
1
Safety
Seclidemstat
for Sarcoma
Tampa, FL
Any Age
All Sexes
Phase 1
Recruiting
Metastatic
Tampa, FL
Any Age
All Sexes
This study is evaluating whether a drug called seclidemstat may help treat sarcoma.
Phase-Based Estimates
2
Effectiveness
3
Safety
Vigil
for Neoplasms, Connective and Soft Tissue
Saint Louis, MO
Any Age
All Sexes
Phase 3
Waitlist Available
Metastatic
Saint Louis, MO
Any Age
All Sexes
This study is evaluating whether a new treatment for Ewing's sarcoma can improve survival.
Phase-Based Estimates
1
Effectiveness
1
Safety
Diffusion Weighted Magnetic Resonance Imaging
for Sarcoma
Memphis, TN
Any Age
All Sexes
Waitlist Available
Metastatic
Memphis, TN
Any Age
All Sexes
Children with sarcomas are routinely assessed with a variety of imaging techniques that involve the use of ionizing radiation. These include computed tomography (CT), nuclear bone scan, and positron emission tomography-CT (PET-CT). Pediatric sarcoma patients undergo many imaging studies at the time of diagnosis, during therapy and for years following completion of therapy. Because children are in a stage of rapid growth, their tissues and organs are more susceptible to the harmful effects of ionizing radiation than are adults. Furthermore, compared to adults, children have a longer life expectancy and, therefore, a longer period of time in which to develop the adverse sequelae of radiation exposure, such as the development of second malignancies. Alternative experimental methods of measuring tumor response will be compared to current standard of care measures to determine if the experimental method is equivalent to methods currently being used. Investigators wish to determine if they can reduce patient's exposure to the harmful effects of ionizing radiation by replacing imaging studies that use radiation with whole body diffusion weighted magnetic resonance imaging (DW-MRI) which does not use any radiation. They also want to know if DW-MRI measurements of the tumor can tell how well the tumor is responding to therapy. There have been studies in adults with cancer that have shown that DW-MRI provides useful information about how tumors are responding to therapy. There have only been very small studies of DW-MRI in children with tumors in the body. Therefore, the role of DW-MRI in pediatric sarcoma patients is not yet known and it is still experimental. This study might give us important information that could help us treat other children with bone or soft tissue sarcomas in the future.
Phase-Based Estimates
2
Effectiveness
3
Safety
Ganitumab
for Sarcoma
Yuma, AZ
< 65
All Sexes
Phase 3
Waitlist Available
Metastatic
Yuma, AZ
< 65
All Sexes
This study is evaluating whether a combination of chemotherapy and ganitumab is more effective than chemotherapy alone in treating patients with newly diagnosed Ewing sarcoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Donor NK Cell Infusion
for Sarcoma
Milwaukee, WI
Any Age
All Sexes
Phase 2
Waitlist Available
Grade III
Milwaukee, WI
Any Age
All Sexes
This study is evaluating whether a cellular and adoptive immunotherapy approach can improve disease control rate for people with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance High Intensity Focused Ultrasound
for Cancer
Washington, United States
< 65
All Sexes
Phase 1
Waitlist Available
1 Prior Treatment
Washington, United States
< 65
All Sexes
This study is evaluating whether a new type of surgery may be effective for treating tumors in children and young adults.
Phase-Based Estimates
1
Effectiveness
1
Safety
MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Cyclophosphamide
for Relapse
Dallas, TX
< 65
All Sexes
Phase 1
Recruiting
Locally Advanced
Dallas, TX
< 65
All Sexes
This study is evaluating whether a combination of two drugs may help treat certain types of cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Irinotecan
for Sarcoma
New York, NY
< 65
All Sexes
Phase 2
Recruiting
1 Prior Treatment
New York, NY
< 65
All Sexes
The purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on Ewing sarcoma. Irinotecan and temozolomide are chemotherapy drugs that are used very often to treat pediatric patients at MSKCC. The investigators have used these two drugs for many years to treat patients with Ewing sarcoma whose cancer has relapsed. For patients with newly diagnosed Ewing sarcoma the current standard of care at MSKCC is a five drug chemotherapy regimen in combination with surgery and/or radiation therapy. This standard regimen is called the EFT regimen. . Some patients with Ewing sarcoma do not have their cancer cured by the chemotherapy and surgery/radiation therapy. This study adds the chemotherapy drugs called irinotecan and temozolomide to the standard EFT regimen. The investigators are trying to improve the success of standard therapy by adding these drugs. The use of irinotecan and temozolomide in this study is experimental because they have not been used before in patients with newly diagnosed Ewing sarcoma. However the investigators have found these drugs to be effective in patients with relapsed Ewing sarcoma. It is not known if adding these two drugs will improve the outcomes of patients treated for Ewing sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Metronomic Cyclophosphamide
for Spongioblastoma
Saint Louis, MO
< 65
All Sexes
Phase 1
Recruiting
Saint Louis, MO
< 65
All Sexes
This study is evaluating whether two drugs may help prevent tumors from growing after stem cell transplant.
Phase-Based Estimates
2
Effectiveness
3
Safety
Dexrazoxane
for Neuroectodermal Tumors, Primitive, Peripheral
Las Vegas, NV
< 65
All Sexes
Phase 3
Waitlist Available
Metastatic
Las Vegas, NV
< 65
All Sexes
This study is evaluating whether a new chemotherapy drug combination is better than the standard 5-drugs for patients with extracranial Ewing sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Autologous Hematopoietic Stem Cell Transplantation
for Germ Cell Cancer
Duarte, CA
< 65
All Sexes
Phase 1
Waitlist Available
High Risk
Duarte, CA
< 65
All Sexes
This study is evaluating whether a stem cell transplant can be used to treat patients with solid tumors.
Phase-Based Estimates
1
Effectiveness
1
Safety
Seclidemstat
for Low Grade Fibromyxoid Sarcoma
Santa Monica, CA
Any Age
All Sexes
Phase 1 & 2
Waitlist Available
Santa Monica, CA
Any Age
All Sexes
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
Phase-Based Estimates
1
Effectiveness
1
Safety
PRT2527
for Cancer
Fairfax, VA
18+
All Sexes
Phase 1
Recruiting
Grade I
Fairfax, VA
18+
All Sexes
This is a Phase 1 dose-escalation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.
Phase-Based Estimates
1
Effectiveness
1
Safety
Temozolomide
for Neuroblastoma
Cincinnati, OH
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Cincinnati, OH
< 65
All Sexes
This study is evaluating whether a new drug may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
CLR 131
for Cancer
Toronto, Canada
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Toronto, Canada
< 65
All Sexes
This study is evaluating whether a drug called CLR 131 may help treat cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Nab-Paclitaxel
for Sarcoma, Ewing
Los Angeles, CA
< 65
All Sexes
Phase 2
Recruiting
Grade I
Los Angeles, CA
< 65
All Sexes
This study is evaluating whether a combination of two chemotherapy drugs may help treat children with certain types of cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance High Intensity Focused Ultrasound
for Neuroblastoma
Washington, United States
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Washington, United States
< 65
All Sexes
This study is evaluating whether a combination of a drug and a focused ultrasound may be effective for treating children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Zoledronate
for Leukemia
Madison, WI
< 65
All Sexes
Phase 1
Recruiting
Class I
Madison, WI
< 65
All Sexes
This study is evaluating whether a transplant of white blood cells from a close relative may help leukemia patients recover following chemotherapy.
Phase-Based Estimates
1
Effectiveness
1
Safety
Olaparib
for Sarcoma, Ewing
Boston, MA
Any Age
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Boston, MA
Any Age
All Sexes
This research study is a Three arm Phase I clinical trial, which tests the safety of an investigational drug or combination of drugs and also tries to define the appropriate dose of the combination of investigational drugs to use for further studies. "Investigational" means that the combination of drugs is being studied. It also means that the FDA has not yet approved the combination of drugs for your type of cancer. Olaparib works by blocking the activity of a protein called poly (ADP-ribose) polymerase (PARP) which is involved in DNA repair. Cancer cells rely on PARP to repair their DNA and enable them to continue dividing. Olaparib has been used in research studies with other cancers. Information from those other research studies suggests that this drug may help to treat patients with Ewing's sarcoma. The investigational drug olaparib is not approved for any use outside of research studies. Temozolomide (Temodar) is approved by the FDA for the treatment of a type of brain tumor, glioblastoma. It has been studied in Ewing sarcoma in previous research studies. While it is not approved by the FDA for Ewing sarcoma, it is considered part of standard treatment for relapsed disease. Irinotecan is approved by the FDA for the treatment of gastrointestinal cancers. It has been studied in Ewing sarcoma in previous research studies. While it is not approved by the FDA for Ewing sarcoma, it is considered part of standard treatment for relapsed disease. Laboratory studies suggest that the combination of olaparib and temozolomide and/or irinotecan may help kill Ewing sarcoma or rhabdomyosarcoma cells. In this research study, the investigators are looking for the highest dose of the combination of olaparib and irinotecan and/or temozolomide that can be given safely. The investigators will also begin to collect information about the effects of the combination on Ewing sarcoma and rhabdomyosarcoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Methionine
for Cancer
Memphis, TN
Any Age
All Sexes
Phase 2
Recruiting
Grade I
Memphis, TN
Any Age
All Sexes
This study is evaluating whether a radioactive form of an amino acid may help doctors better understand and treat tumors.
Other Trials to Consider
Ideal Binary Mask
for Hearing Loss
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase < 1
Recruiting
Logan, UT
18+
All Sexes
Gemcitabine
for Sarcoma
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1
Recruiting
Grade II
Winston-Salem, NC
18+
All Sexes
Efineptakin Alfa
for Infections
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1
Recruiting
Grade II
New York, NY
18+
All Sexes
CBX-12
for Small Cell Lung Carcinoma
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
Locally Advanced
Austin, TX
18+
All Sexes
Liposomal Annamycin (L-Annamycin)
for Lung Cancer
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
Grade I
Columbus, OH
18+
All Sexes
Metastasectomy
for Sarcoma
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
Metastatic
Buffalo, NY
18+
All Sexes
Hypofractionated Proton Beam Therapy
for Sarcoma
Phase-Based Estimates
1
Effectiveness
2
Safety
Phase 2
Waitlist Available
Class II
Baltimore, MD
18+
All Sexes
LY2880070
for Ewing Sarcoma
Phase-Based Estimates
1
Effectiveness
2
Safety
Phase 2
Recruiting
Locally Advanced
New York, NY
Any Age
All Sexes
Intensity Modulated Radiation Therapy (IMRT)
for Sarcoma
Phase-Based Estimates
1
Effectiveness
2
Safety
Phase 2
Recruiting
Metastatic
Tampa, FL
18+
All Sexes
Sotorasib
for Colorectal Cancer
Phase-Based Estimates
2
Effectiveness
3
Safety
Phase 3
Recruiting
Metastatic
Columbus, OH
18+
All Sexes
Nab-Paclitaxel
for Sarcoma, Ewing
Phase-Based Estimates
1
Effectiveness
2
Safety
Phase 2
Recruiting
Grade I
Los Angeles, CA
< 65
All Sexes
Sterotactic Body Radiotherapy
for Prostate Cancer
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Toronto, Canada
18+
Male
Genetic Counseling
for Melanoma
Phase-Based Estimates
1
Effectiveness
1
Safety
Waitlist Available
Boston, MA
18+
All Sexes
Questionnaire Administration
for Sarcoma
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Houston, TX
18+
All Sexes
Popular Categories
Top 10 Sarcoma Clinical Trials
Sarcoma Clinical Trials 2022
Top 10 Genital Herpes Clinical Trials
Genital Herpes Clinical Trials
Top 10 Emphysema Clinical Trials
Emphysema Clinical Trials
Top 10 Cardiovascular Clinical Trials
Cardiovascular Clinical Trials
Top 10 Soft Tissue Sarcoma Clinical Trials
Soft Tissue Sarcoma Clinical Trials 2022
Top 10 Neuroendocrine Tumor Clinical Trials
Neuroendocrine Tumor Clinical Trials
Top 10 Synovial Sarcoma Clinical Trials
Synovial Sarcoma Clinical Trials
Top 10 Rexulti Clinical Trials
Rexulti Clinical Trials
Top 10 Ticagrelor Clinical Trials
Ticagrelor Clinical Trials
Top 10 Tykerb Clinical Trials
Tykerb Clinical Trials
Top 10 Chantix Clinical Trials
Chantix Clinical Trials
Top 10 Movantik Clinical Trials
Movantik Clinical Trials
Top 10 Xiidra Clinical Trials
Xiidra Clinical Trials
Top 10 Tudorza Pressair Clinical Trials
Tudorza Pressair Clinical Trials
Top 10 Nuedexta Clinical Trials
Nuedexta Clinical Trials
Relevant Clinical Trials
GBM Clinical Trials
Arthritis Clinical Trials 2022
Allergy Clinical Trials
NASH Clinical Trials
Narcolepsy Clinical Trials 2022
Infertility Clinical Trials
Anxiety Clinical Trials 2022
Heart Failure Clinical Trials 2022
Glaucoma Clinical Trials
Mental Health Clinical Trials
Gastroparesis Clinical Trials 2022
Osteoporosis Clinical Trials
Migraine Clinical Trials 2022
Transcranial Magnetic Stimulation Clinical Trials
Chronic Pain Clinical Trials
Skin Care Clinical Trials 2022
Vitiligo Clinical Trials 2022
Epilepsy Clinical Trials
Vaccine Clinical Trials 2022
Pregnancy Clinical Trials
Top Oncology Trials
Cancer Clinical Trials 2022
Pancreas Cancer Clinical Trials
Prostate Cancer Clinical Trials
Breast Cancer Clinical Trials
Pancreatic Cancer Clinical Trials
Oncology Clinical Trials
Melanoma Clinical Trials 2022
Multiple Myeloma Clinical Trials
Triple Negative Breast Cancer Clinical Trials
Ovarian Cancer Clinical Trials 2022
Lung Cancer Clinical Trials 2022
Colon Cancer Clinical Trials
CLL Clinical Trials 2022
Small Cell Lung Cancer Clinical Trials 2022
Esophageal Cancer Clinical Trials 2022
Mesothelioma Clinical Trials 2022
Leukemia Clinical Trials
AML Clinical Trials
Bladder Cancer Clinical Trials
Cholangiocarcinoma Clinical Trials 2022
Popular Clinical Trials
COVID Clinical Trials 2022
Depression Clinical Trials 2022
ALS Clinical Trials 2022
Coronavirus Clinical Trials 2022
IVF Clinical Trials
Marijuana Clinical Trials 2022
Type 1 Diabetes Clinical Trials
Lupus Clinical Trials 2022
Tinnitus Clinical Trials
PTSD Clinical Trials 2022
Diabetes Clinical Trials 2022
Rheumatoid Arthritis Clinical Trials
Psoriasis Clinical Trials 2022
Multiple Sclerosis Clinical Trials 2022
Obesity Clinical Trials 2022
Psilocybin Clinical Trials
Weight Loss Clinical Trials 2022
Osteoarthritis Clinical Trials
Lyme Disease Clinical Trials
Retinitis Pigmentosa Clinical Trials
Back to top
461 2nd St., San Francisco, CA
hello@withpower.com
(415) 900-4227
About Us
Join The Team!
Conditions
ADHD
ALS
Asthma
Autism
Eczema
IVF
MDS
Osteoarthritis
Psoriasis
Rheumatoid Arthritis
Locations
Colorado
Florida
Indiana
Maine
Massachusetts
Michigan
New York
Ohio
Pennsylvania
Texas
Cancer Related
Chronic Lymphocytic Leukemia
Esophageal
Leukemia
Lymphoma
Melanoma
Multiple Myeloma
Pancreatic Cancer
Prostate Cancer
Small Cell Lung Cancer
Triple Negative Breast Cancer
Treatments
Contrave
Dsuvia
Epidiolex
Ibrutinib
Kybella
Orkambi
Testosterone
Xarelto
Xiidra
Yondelis
Cities
Anaheim, CA
Baltimore, MD
Boston, MA
Chicago, IL
High Point, NC
Houston, TX
Las Vegas, NV
Los Angeles, CA
Miami, FL
San Diego, CA
Terms of Service
Privacy Policy